Rob Brierley

The April 2026 issue of @lancetgastrohep.bsky.social is out today at www.thelancet.com/gastrohep

This month's issue features content on #IBD, #cirrhosis, #pancreaticcancer, #viralhepatitis, #MASLD + more...

#GastroSky #MedSky #LiverSky

Our March issue is now online:

www.thelancet.com/journals/lan...

Our journal is #OpenAccess, so you are free to explore all of our content. But these hashtags offer a flavour: #malaria #HIV #Streptococcus #PCV #RiftValleyFever #pertussis #tuberculosis #TB #AMR

#IDSky #ClinMicro #TBSky #OA

🆕 Out now: the inaugural issue of The Lancet Regional Health – Africa, a Gold Open Access journal.

"As a journal, we stand for the decolonization of health and medical research in Africa."

Explore the full issue 👉 spkl.io/63320AIdt8

Just presented at #ECCO2026 - 10-year data from the LIR!C trial comparing ileocaecal resection vs infliximab for ileal Crohn’s disease

Now published in @lancetgastrohep.bsky.social

www.thelancet.com/journals/lan...

#ECCO26 #GastroSky #MedSky #IBDSky

Safety, pharmacokinetics, and preliminary efficacy of VS-01, an intraperitoneal liposomal infusion, in patients with decompensated liver cirrhosis, ascites, and covert hepatic encephalopathy: a phase ... VS-01 was generally well tolerated with a favourable safety profile in patients with decompensated liver cirrhosis, ascites, and covert hepatic encephalopathy. The results of this study supported the ...

New research - Safety, pharmacokinetics, and preliminary efficacy of VS-01, an intraperitoneal liposomal infusion, in patients with decompensated liver cirrhosis, ascites, and covert hepatic encephalopathy: a phase 1b study

www.thelancet.com/journals/lan...

#LiverSky #MedSky

Our March issue is now live at www.thelancet.com/gastrohep!

Content includes: #alcohol, #IBD, #HBV, #MASLD, #SIMD (#SIBO) + more!

#GastroSky #LiverSky #MedSky

Efimosfermin alfa (BOS-580) once per month in people with metabolic dysfunction-associated steatohepatitis with F2 or F3 fibrosis: results from a 24-week, randomised, double-blind, placebo-controlled,... In this phase 2 trial, treatment with efimosfermin once per month was generally well tolerated in participants with biopsy-confirmed MASH and F2 or F3 fibrosis. These results support the further devel...

New @thelancet.com - Efimosfermin alfa (BOS-580) once per month in people with MASH with F2 or F3 fibrosis: results from a 24-week, randomised, double-blind, placebo-controlled, phase 2 trial

www.thelancet.com/journals/lan...

#LiverSky #MedSky #EndoSky #GastroSky

New World Report in @thelancet.com examines the controversial trial of hepatitis B virus birth dose vaccination that was planned in Guinea-Bissau

#HepSky #LiverSky #IDSky

🚀 Just launched – our new #goldopenaccess journal on medical imaging and theranostics!
Learn more about the journal’s mission and explore related content from The Lancet Group today: hubs.li/Q041CgFF0

#medsky

New research: Long-term oncological outcomes following algorithm-based vs usual care for the early recognition & management of complications after pancreatic resection: post-hoc analysis of a stepped-wedge cluster-randomised trial

www.thelancet.com/journals/lan...

#GastroSky #OncSky #MedSky

EMA grants conditional marketing authorisation for semaglutide for treatment of non-cirrhotic MASH with liver fibrosis

#LiverSky #MedSky

NHS to increase accuracy of bowel cancer test in England Increased sensitivity of test that detects the second deadliest cancer will save hundreds of lives, oncologists say

NHS England to lower threshold for the amount of blood detected by FIT that triggers further investigation from 120 to 80 micrograms of blood/g of stool by 2028

www.theguardian.com/society/2026...

#GastroSky #MedSky #OncSky

Safety and efficacy of CRS3123 in adults with a primary episode or first recurrence of Clostridioides difficile infection: a phase 2, randomised, double-blind, multicentre, vancomycin-controlled study Both doses of CRS3123 were deemed safe and well tolerated and showed efficacy similar to vancomycin at the TOC visit, with lower rates of recurrence. Together, these data support further development o...

New Research

Safety and efficacy of CRS3123 in adults with a primary episode or first recurrence of Clostridioides difficile infection: a phase 2, randomised, double-blind, multicentre, vancomycin-controlled study

www.thelancet.com/journals/lan...

Guinea-Bissau Suspends Trump-Backed Hep B Vaccine Trial for Ethical Review But HHS spokesman says the study 'is proceeding as planned'

Guinea-Bissau Suspends Trump-Backed Hep B Vaccine Trial for Ethical Review www.medpagetoday.com/infectiousdi...

#LiverSky #IDSky #HepSky #MedSky

NEW RESEARCH—Long-term outcomes of abatacept in individuals at risk of developing rheumatoid arthritis (ALTO): a randomised, double-blind, placebo-controlled trial bit.ly/4pSERqq

Plus, linked Comment bit.ly/49v27Ga #Medsky #Rheumsky

ASCO Gastrointestinal Cancers Symposium 2026 A prespecified interim analysis of HERIZON-GEA-01 indicates that zanidatamab—a dual HER2-targeted monoclonal antibody that crosslinks neighbouring HER2 receptors and causes receptor clustering—might b...

News - ASCO Gastrointestinal Cancers Symposium 2026

www.thelancet.com/journals/lan...

#GI26 #ASCOGI #GastroSky #OncSky #MedSky

Mechanisms and pathophysiology leading to development of small intestinal microbial dysbiosis Small intestinal microbial dysbiosis (SIMD) describes clinical syndromes attributed to overabundance of microbes within the small intestine. Usually attributed to bacteria (but also less commonly to a...

New review - Mechanisms and pathophysiology leading to development of small intestinal microbial dysbiosis

www.thelancet.com/journals/lan...

#GastroSky #MedSky

New Comment - Menopause and inflammatory bowel disease: more questions than answers

www.thelancet.com/journals/lan...

#GastroSky #MedSky #IBDSky

Controversial CDC-Funded Hep B Study Halted An official from the Africa CDC said if it moves forward, it must meet ethical criteria

Controversial CDC-Funded Hep B Study Halted www.medpagetoday.com/infectiousdi...

ALG-000184 (pevifoscorvir sodium) monotherapy in participants with chronic HBV infection: a phase 1, multicentre, randomised, dose escalation trial ALG-000184 was safe and well tolerated, demonstrated predictable pharmacokinetic properties, and reduced HBV DNA and HBV RNA at all doses regardless of HBeAg status. These results support the evaluati...

New research - ALG-000184 (pevifoscorvir sodium) monotherapy in participants with chronic HBV infection: a phase 1, multicentre, randomised, dose escalation trial

www.thelancet.com/journals/lan...

#HepSky #IDSky #LiverSky #MedSky

Cyclic exclusive enteral nutrition versus partial enteral nutrition to maintain long-term drug-free remission in paediatric Crohn's disease (CD-HOPE): an open-label, endpoint-blinded, randomised contr... C-EEN was superior to PEN in maintaining clinical remission over 1 year in paediatric patients with Crohn's disease responding to EEN induction therapy. These findings suggest a new way to use nutriti...

New research - Cyclic exclusive enteral nutrition versus partial enteral nutrition to maintain long-term drug-free remission in paediatric Crohn's disease (CD-HOPE): an open-label, endpoint-blinded, randomised controlled trial

www.thelancet.com/journals/lan...

#GastroSky #MedSky #IBDSky

Disorders of the gastrointestinal tract can have a major impact on individuals' wellbeing, nutrition, and quality of life.

In @lancetgastrohep.bsky.social, authors summarise current knowledge of age-related changes of the gastrointestinal tract: spkl.io/63325AWxGS

Efficacy and safety of subcutaneous guselkumab induction therapy in participants with moderately to severely active ulcerative colitis (ASTRO): a double-blind, treat-through, randomised, placebo-contr... Subcutaneous guselkumab induction and maintenance was safe and efficacious for 24 weeks in participants with moderately to severely active ulcerative colitis, establishing a fully subcutaneous guselku...

New research - Efficacy and safety of subcutaneous guselkumab induction therapy in participants with moderately to severely active ulcerative colitis (ASTRO): a double-blind, treat-through, randomised, placebo-controlled, phase 3 trial

www.thelancet.com/journals/lan...

#GastroSkt #MedSky #IBDSky

📢 Our first issue of 2026 is now live! The latest issue highlights cutting-edge research in gene therapy, immunology, neuroscience, and translational medicine.

🔗 Read the full issue online

Globally, metabolic dysfunction-associated steatotic liver disease (MASLD) is the most common chronic liver disease.

In @lancetgastrohep.bsky.social, a new Review summarises recent breakthroughs and potential future developments: spkl.io/63326Amv4o

New research - Appendicectomy versus switching to a JAK inhibitor in inducing remission in patients with active ulcerative colitis after biologic therapy failure (COSTA): 1-year results of a multicentre, prospective, cohort study

www.thelancet.com/journals/lan...

#IBD #GastroSky #MedSky

Our Feb 2026 issue is now live at www.thelancet.com/gastrohep!

Content includes #colorectalcancer, paediatric #ulcerativecolitis, #cholangiocarcinoma, #viralhepatitis, #MASH + more…

#GastroSky #LiverSky #MedSky #OncSky

Metabolic dysfunction-associated steatotic liver disease: heterogeneous pathomechanisms and effectiveness of metabolism-based treatment
www.thelancet.com/journals/lan...
#MASLD #obesity #lipodystrophy
#OpenAccess

#MedSky #EndoSky #LiverSky

New Editorial - ACIP’s HBV birth-dose vaccine recommendations: a fiasco

www.thelancet.com/journals/lan...

#HepSky #LiverSky #MedSky #IDSky